Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 10:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 388 matching trials from the live ClinicalTrials.gov search.
Filters: "early Alzheimer" Condition: Alzheimer's Disease Clear all
Terminated Phase 3 Interventional

Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects

NCT06304883
View directory record Official record
Conditions
Early Alzheimer's Disease
Interventions
Experimental: ALZ-801
Drug
Lead sponsor
Alzheon Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
29
States / cities
Phoenix, Arizona • Sun City, Arizona • Costa Mesa, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 11, 2026, 10:20 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Cognitive Screening Made Easy for PCPs

NCT05082883
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Cognitive Decline
Interventions
Risk Assessment Cognitive Screening
Diagnostic Test
Lead sponsor
University of Texas at Austin
Other
Eligibility
60 Years and older
Enrollment
152 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Oct 11, 2026, 10:20 AM EDT
Terminated No phase listed Observational

Detecting Early Myocardial Infiltration w/Amyloid & Light Chain Deposition Disease in Multiple Myeloma Subjects

NCT01018927
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Administering three additional MRI images
Device
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 80 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Oct 11, 2026, 10:20 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Early-onset Alzheimer's Disease Phenotypes: Neuropsychology and Neural Networks

NCT03153371
View directory record Official record
Conditions
Alzheimer Disease, Early Onset, Alzheimer Disease, Alzheimer Disease, Late Onset, Dementia, Alzheimer Type, Logopenic Progressive Aphasia, Primary Progressive Aphasia, Visuospatial/Perceptual Abilities, Posterior Cortical Atrophy, Executive Dysfunction, Corticobasal Degeneration, Ideomotor Apraxia
Interventions
Not listed
Lead sponsor
University of California, Los Angeles
Other
Eligibility
50 Years to 85 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Oct 11, 2026, 10:20 AM EDT
Recruiting Phase 3 Interventional

Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

NCT06563895
View directory record Official record
Conditions
Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis, Cardiomyopathies, Heart Diseases, Polyneuropathies
Interventions
Acoramidis, Placebo oral tablet
Drug
Lead sponsor
Eidos Therapeutics, a BridgeBio company
Industry
Eligibility
18 Years to 75 Years
Enrollment
587 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
40
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 31 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 11, 2026, 10:20 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Predicting Pre-dementia

NCT07516119
View directory record Official record
Conditions
Mild Cognitive Impairment (MCI), Alzheimer Dementia (AD), Alzheimer Disease (AD), APOE-4 Positive
Interventions
Not listed
Lead sponsor
Prevention Research Consortium Corp.
Other
Eligibility
55 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 11, 2026, 10:20 AM EDT
Not listed Not applicable Interventional

tDCS and Cognitive Training for Mild Cognitive Impairment and Alzheimer's Dementia

NCT04507815
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment
Interventions
Active Transcranial Direct Current Stimulation (tDCS), Sham Transcranial Direct Current Stimulation (tDCS)
Device
Lead sponsor
Minneapolis Veterans Affairs Medical Center
Federal
Eligibility
60 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced Oct 11, 2026, 10:20 AM EDT
Recruiting Not applicable Interventional

Lifestyle Interventions for the Treatment of Early Onset Alzheimer's Disease Study

NCT05573490
View directory record Official record
Conditions
Alzheimer Disease, Early Onset
Interventions
Cognitive Training, Tai Chi- Qi Gong, Brain Games, Stretching
Device · Behavioral
Lead sponsor
Indiana University
Other
Eligibility
40 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 11, 2026, 10:20 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)

NCT05269394
View directory record Official record
Conditions
Alzheimers Disease, Dementia, Alzheimers Disease, Familial
Interventions
E2814, Lecanemab, Matching Placebo (E2814)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 80 Years
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
12
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 11, 2026, 10:20 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease

NCT02565511
View directory record Official record
Conditions
Alzheimers Disease
Interventions
CAD106 Immunotherapy, Placebo to CAD106, CNP520, Placebo to CNP520, Alum
Biological · Other · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
60 Years to 75 Years
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
78
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2021 · Synced Oct 11, 2026, 10:20 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Amyloid Plaque and Tangle Imaging in Aging and Dementia

NCT00355498
View directory record Official record
Conditions
Memory Disorders, Alzheimer's Disease
Interventions
Not listed
Lead sponsor
University of California, Los Angeles
Other
Eligibility
30 Years and older
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 6, 2020 · Synced Oct 11, 2026, 10:20 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)

NCT03114657
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Crenezumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years to 85 Years
Enrollment
806 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
48
States / cities
Scottsdale, Arizona • Fayetteville, Arkansas • Little Rock, Arkansas + 44 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2020 · Synced Oct 11, 2026, 10:20 AM EDT
Completed Not applicable Interventional

Resilient Together for Dementia

NCT06421545
View directory record Official record
Conditions
Alzheimer's Disease and Related Dementias
Interventions
Resilient Together for Dementia
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
65 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 11, 2026, 10:20 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

OCT Angiography and NRAI in Dementia

NCT03761381
View directory record Official record
Conditions
Alzheimer Disease, Dementia, Mild Cognitive Impairment
Interventions
Optical Coherence Tomography Angiography (OCTA) Imaging, Noninvasive Retinal Amyloid Imaging (NRAI)
Device
Lead sponsor
Oregon Health and Science University
Other
Eligibility
55 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 11, 2026, 10:20 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Treatment of Mild Cognitive Impairment With Transcutaneous Vagal Nerve Stimulation

NCT03359902
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Transcutaneous vagal nerve stimulation, Sham stimulation
Device
Lead sponsor
University of Florida
Other
Eligibility
60 Years to 89 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
3
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 24, 2023 · Synced Oct 11, 2026, 10:20 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Posiphen® Dose-Finding, Biomarker Study in Early Alzheimer's and Parkinson's Patients

NCT04524351
View directory record Official record
Conditions
Alzheimer Disease, Parkinson Disease
Interventions
Posiphen, Placebo
Drug
Lead sponsor
Annovis Bio Inc.
Industry
Eligibility
45 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
13
States / cities
Stamford, Connecticut • DeLand, Florida • Hallandale, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Oct 11, 2026, 10:20 AM EDT
Completed No phase listed Observational

Evaluating the Relationship Between Tau PET Imaging and CSF Biomarkers of AD (Alzheimer Disease) in Humans

NCT03287765
View directory record Official record
Conditions
Alzheimer Disease
Interventions
18F-AV-1451
Drug
Lead sponsor
Tammie L. S. Benzinger, MD, PhD
Other
Eligibility
65 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 8, 2023 · Synced Oct 11, 2026, 10:20 AM EDT
Recruiting Not applicable Interventional

Evaluating Novel Healthcare Approaches to Nurturing and Caring for Hospitalized Elders

NCT05929703
View directory record Official record
Conditions
Delirium, Neurocognitive Disorders, Mild Cognitive Impairment, Alzheimer Disease, Aging, Family Support, Family Members, Caregiver Burden, Implementation Science, Patient Satisfaction
Interventions
HELP, FAM-HELP
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
70 Years and older
Enrollment
1,900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
7
States / cities
Orange, California • Portland, Maine • Ann Arbor, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 11, 2026, 10:20 AM EDT
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

RQC for the Prevention of Alzheimer's Disease and Retinal Amyloid-β

NCT06470061
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Cognitive Decline
Interventions
Resveratrol, Quercetin, and Curcumin (RQC), Curcumin
Drug
Lead sponsor
Zaparackas and Knepper LTD
Other
Eligibility
50 Years to 90 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Oct 11, 2026, 10:20 AM EDT
Completed Not applicable Interventional

Digital Detection of Dementia (D Cubed) Studies: D3

NCT06224205
View directory record Official record
Conditions
Alzheimer Disease and Related Dementias (ADRD)
Interventions
Passive Digital Marker for screening for ADRD
Other
Lead sponsor
Indiana University
Other
Eligibility
65 Years and older
Enrollment
1,281 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 11, 2026, 10:20 AM EDT
Active, not recruiting No phase listed Observational

Vanderbilt Memory and Aging Project

NCT05372159
View directory record Official record
Conditions
Alzheimer Disease, Aging, Aged, 80 and Over, Biomarkers, Brain, Case-Control Studies, Cognitive Dysfunction, Neuropsychological Tests
Interventions
none, observational study
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
60 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 11, 2026, 10:20 AM EDT
Completed Phase 2 Interventional Results available

Montelukast Therapy on Alzheimer's Disease

NCT03991988
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Montelukast, Placebo oral tablet
Drug
Lead sponsor
Emory University
Other
Eligibility
50 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
4
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 7, 2024 · Synced Oct 11, 2026, 10:20 AM EDT
Not yet recruiting Not applicable Interventional

CMN LIFU for Enhanced Glymphatic Clearance in Amyloid-Positive MCI

NCT07866768
View directory record Official record
Conditions
Alzheimer's Disease (AD), Mild Cognitive Impairment (MCI), Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease
Interventions
ATTN201 Focused Ultrasound to the CMN, ATTN201 Unfocused Ultrasound
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
65 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 11, 2026, 10:20 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Senolytic Therapy to Modulate Progression of Alzheimer's Disease

NCT04063124
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Dasatinib + Quercetin
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
65 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 6, 2023 · Synced Oct 11, 2026, 10:20 AM EDT